SFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK.

ABSTRACT:

Objectives

To assess the economic impact of introducing into clinical practice in the UK the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test for guiding the management of pre-eclampsia.

Methods

We used an economic model estimating the incremental value of information, from a UK National Health Service payer's perspective, generated by the sFlt-1/PlGF ratio test, compared with current diagnostic procedures, in guiding the management of women with suspected pre-eclampsia. The economic model estimated costs associated with the diagnosis and management of pre-eclampsia in pregnant women between 24 + 0 and 36 + 6 weeks' gestation, managed in either a 'test' scenario in which the sFlt-1/PlGF test is used in addition to current diagnostic proc

SUBMITTER: Vatish M 

PROVIDER: S-EPMC5215695 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature